Skip to main content

elahere

Generic: mirvetuximab soravtansine-gynx

elahere: sourced relationships with 1 company · 1 FDA decision.

elahere evidence translation

What we can confirm

What it means

Source-backed records connect elahere to IMGN; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could elahere → IMGN affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
ImmunoGen, Inc. (IMGN)
developer · Reported 2023-03-01 · Current development: unknownSource
FRα positive, platinum-resistant epithelial ovarian, fallopi…
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE ELAHERE ® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test [see Dosage and Administration ( 2.1 )]. ELAHERE is a folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate indicated for the treatment o(IMGN)FDA ↗
BLA761310Type 1 - New Molecular EntityOrphan DrugPriorityOtherInjectable

Frequently asked questions

Which companies have sourced relationships with elahere?

elahere has dated SEC/FDA relationship records for ImmunoGen, Inc..

What is elahere's latest FDA decision?

The most recent tracked FDA decision for elahere is Approval for 1 INDICATIONS AND USAGE ELAHERE ® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test [see Dosage and Administration ( 2.1 )]. ELAHERE is a folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate indicated for the treatment o, dated November 14, 2022.